StocksMedium•13 November 2026•
1 min read
Rezolute Raises $100M Following Successful Ersodetug Phase 3 Trial
Key Facts
1Rezolute achieved its Phase 3 primary endpoint for ersodetug in tumor hyperinsulinism.
2The company priced a public offering of common stock and pre-funded warrants to raise approximately $100 million at $3.87 per share.
Rezolute achieved its Phase 3 primary endpoint for the drug ersodetug, which is designed to treat tumor hyperinsulinism. Benzinga reported that the company priced a public offering of common stock and pre-funded warrants to raise approximately $100 million at a price of $3.87 per share.
Rezolute, trading under the ticker RZLT, closed at $3.87 on November 12, 2026, aligning with the public offering price. The company intends to use the proceeds to advance its clinical programs toward commercialization following the positive late-stage data, with the stock reaching a session high of $4.13 on November 12, 2026.